Cantor Fitzgerald Predicts Mesoblast FY2025 Earnings

Mesoblast Limited (NASDAQ:MESO) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Mesoblast in a research report issued to clients and investors on Tuesday, March 4th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($0.70) for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Mesoblast’s current full-year earnings is ($0.70) per share.

MESO has been the subject of a number of other research reports. Jefferies Financial Group lowered Mesoblast from a “buy” rating to a “hold” rating in a research note on Monday, December 23rd. Piper Sandler reissued an “overweight” rating and issued a $24.00 target price (up from $15.00) on shares of Mesoblast in a report on Friday, February 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Mesoblast has an average rating of “Moderate Buy” and an average target price of $18.00.

Mesoblast Stock Performance

MESO stock opened at $14.82 on Thursday. Mesoblast has a 52 week low of $2.00 and a 52 week high of $22.00. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.21. The firm’s fifty day moving average is $17.99 and its 200 day moving average is $12.31.

Institutional Investors Weigh In On Mesoblast

A number of large investors have recently made changes to their positions in the company. Bank of America Corp DE grew its position in shares of Mesoblast by 1,503.3% during the 4th quarter. Bank of America Corp DE now owns 290,728 shares of the company’s stock valued at $5,756,000 after acquiring an additional 272,595 shares during the period. Oaktree Capital Management LP purchased a new stake in Mesoblast in the fourth quarter worth about $3,556,000. Strategic Financial Concepts LLC bought a new position in shares of Mesoblast in the fourth quarter worth about $2,744,000. Prosperity Wealth Management Inc. lifted its position in shares of Mesoblast by 2.0% during the 4th quarter. Prosperity Wealth Management Inc. now owns 93,245 shares of the company’s stock valued at $1,846,000 after buying an additional 1,795 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Mesoblast by 46.4% during the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company’s stock valued at $695,000 after buying an additional 26,959 shares in the last quarter. 1.43% of the stock is currently owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.